Fighting multiple sclerosis is no easy job, though it is a noble one. Biotech company Clene (NASDAQ:CLNN) shot up in Monday afternoon’s trading thanks to some new advancements in its own fight with multiple sclerosis. Investors responded nicely, and we’re that much closer to putting an end to this horrible disease as a result.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest news came from a phase 2 trial of CNM-Au8, a new treatment that targets neuronal structural integrity in the brain. By keeping the brain in better shape, the odds of suffering from multiple sclerosis drop accordingly. The trial, known as VISIONARY-MS, ran for 48 weeks and produced some exciting results. The trial used two different treatments, one with 15 mg of CNM-Au8 and one with 30 mg. Both the 15 and 30 mg treatments showed “white matter integrity,” noted clinical advisor Michael Barnett.
White matter integrity here was measured using a standard measure known as fractional anisotropy. Here, being “highly isotropic” can come with either poor white matter integrity or better white matter integrity. In this case, the highly isotropic figures came back with improved white matter integrity, suggesting success. Further MRI testing found that those who took CNM-Au8 showed “improved myelin integrity.” Levels of myelin integrity are a key indicator in multiple sclerosis, noted Clene’s CEO, Rob Etherington.
Clene’s insiders have a solid level of support as well, based on insider trading activity. Currently, insider sentiment at the company is Positive, and insiders bought $26,200 in shares in the last three months.
